MediWound Investor Relations Material
Latest events
Q2 2024
MediWound
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from MediWound Ltd
Access all reports
MediWound Ltd. specializes in the development, manufacture, and commercialization of innovative therapies for tissue repair and regeneration. The company focuses primarily on enzymatic debridement solutions for the treatment of severe burns, chronic wounds, and other hard-to-heal injuries. MediWound's proprietary technologies are designed to improve the healing process by selectively removing dead or damaged tissue without harming surrounding healthy tissue. The company serves healthcare providers, hospitals, and wound care centers globally, aiming to enhance patient outcomes and reduce treatment costs. MediWound is headquartered in Yavne, Israel, and its shares are listed on the NASDAQ.
Latest articles
Qualcomm: Quality Communication and Semiconductor Innovation
Founded in 1985, Qualcomm has transformed the digital communication industry with CDMA technology and its advanced semiconductor business.
13 Sep 2024
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Novo Nordisk: The Danish Pharmaceutical Titan Revolutionizing Global Healthcare
Novo Nordisk's rise to becoming Europe's largest company, reshaping global healthcare and Denmark's economy.
5 Sep 2024
Ticker symbol
MDWD
Country
🇺🇸 United States